Roche’s ocrelizumab significantly reduced both relapses and disability progression versus interferon beta-1a (Rebif®) in two Phase III studies in multiple sclerosis

Roche today announced positive results from two pivotal studies evaluating the investigational medicine ocrelizumab compared with interferon beta-1a (Rebif®), a standard-of-care therapy, in people with relapsing multiple sclerosis (MS), the most common form of the disease.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news